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ABSTRACT: Vernix caseosa (vernix) is a white creamy substance
covering the skin of the fetus during the last trimester of pregnancy.
The function of vernix has long been debated but no consensus has
been reached. We here report a proteome analysis of vernix using
two-dimensional gel electrophoresis, matrix-assisted laser desorp-
tion/ionization mass spectrometry and liquid chromatography cou-
pled to tandem mass spectrometry. We have identified 41 proteins, of
which 25 are novel to vernix. Notably, 39% of the identified vernix
proteins are components of innate immunity, and 29% have direct
antimicrobial properties. These results form a substantial contribution
to the knowledge of vernix composition and demonstrate that anti-
microbial protection of the fetus and the newborn child is a major and
important function of vernix. (Pediatr Res 60: 430–434, 2006)
Awhite creamy substance designated Vernix caseosa (latinfor “Cheese-like varnish”) covers the skin of the fetus
during the last trimester of pregnancy. The human is the only
species known to produce this substance, and its function has
been debated for decades. Many protective functions have
been proposed, such as antimicrobial protection, heat insula-
tion, moisturization and protection of the skin from macerat-
ing effects of the amniotic fluid. Other functions have also
been suggested, such as hormonal effects, anti-inflammatory
effects, nutritive functions, and facilitation of passage through
the birth canal (1). Furthermore, vernix has been suggested to
constitute a mechanical obstruction to bacterial passage (2).
Recently, it was reported that vernix exhibits a skin cleansing
function (3).
Early studies on whether vernix possesses direct antimicro-
bial activities yielded contradictory results (1,2), most likely
due to use of different antimicrobial assays. However, by
preparation of a protein extract of vernix and identification of
individual components we have proved that vernix contains
potent antimicrobial polypeptides (4,5). Members of the anti-
microbial peptide families -defensins (Human Neutrophil
Peptide, (HNP) 1–3) and cathelicidins (LL-37) have been
identified in vernix, in addition to a number of antimicrobial
proteins, i.e., psoriasin, secretory leukocyte protease inhibitor
(SLPI) and calprotectin (calgranulin A and B) (4–6).
In association with the discussion on the antimicrobial
properties of vernix, there has been a debate on whether vernix
should be left on the skin after birth (7,8). Skin colonization of
neonates was compared after leaving vernix on the skin and
after bathing (removing vernix) the newborn. That study
resulted in no difference in microbial colonization (8). How-
ever, the bathing reduced heat loss, and made the newborns
calm, quiet and comfortable (8). The amount of vernix on the
skin correlates with gestational age (9,10). Preterm infants
lacking vernix have a higher rate of nosocomial and commu-
nity acquired infections (10).
The composition of vernix is water (81%), lipids (9%), and
proteins (10%) (11). Research on vernix has mainly focused
on the lipid fraction (12–15), while the vernix proteins have
long been neglected. However, in a recent study 18 vernix
proteins were identified (5), but a comprehensive proteome
analysis has to our knowledge not been performed of this
material. We have therefore investigated the vernix proteome
by 2-D (two-dimensional) gel electrophoresis, matrix-assisted
laser desorption/ionization mass spectrometry (MALDI-MS)
and liquid chromatography coupled to tandem mass spectrom-
etry (LC-MS/MS), identifying many proteins novel to vernix.
This now brings important insight into the role of vernix
caseosa.
MATERIALS AND METHODS
Collection of vernix caseosa. Vernix caseosa was collected from the skin
of newborns shortly after delivery, and before washing the neonates. The
vernix samples were placed in sterile plastic containers and were immediately
frozen and stored at -20°C until analyzed. All newborns were without prenatal
or perinatal complications, and without clinical signs of infection. The study
was reported to the Data Protection Authority and the sample collection was
approved by the parents.
Peptide/protein extraction. The vernix samples were extracted as recently
described (5). Briefly, the samples were homogenized in 60% acetonitrile
containing 1% (vol/vol) aqueous trifluoroacetic acid (TFA), and extracted
during shaking overnight at 4°C. After centrifugation of the extracts at 10,000
g, the supernatants were lyophilised. The lyophilised material was dissolved
in 0.1% (TFA) and loaded onto OASIS HLB cartridges (Waters). Bound
proteins were eluted with 80% acetonitrile in 0.1% TFA and the eluates were
lyophilized.
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2-D gel electrophoresis. The protein content of samples was determined
by the Bradford assay (16). Sample loads of 350–450 g protein were applied
onto 17-cm Bio-Rad strips of pI 3-10 (Non Linear) via active in-gel rehydra-
tion. The sample (in 9 M urea, 65 mM DTT, 0.5% Igepal CA 630, 1.5%
3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS),
5% ampholyte 3-10, 35 mM Tris, and complete proteinase inhibitor mix
(Roche) was diluted with rehydration buffer (7 M urea, 2 M thiourea, 4%
wt/vol CHAPS, 0.5% Igepal CA 630, 0.5% ampholyte 3–10 and 2.8 mg/mL
DTT) to a final volume of 300 L. The isoelectric focusing was carried out
on a PROTEAN IEF (Bio-Rad) at 20°C as follows: 12 h at 50 V (active
rehydration), 0–500 V for 1 h, 500 V for 1 h, 500–2000 V for 2 h, 2000–8000
V for 1 h and finally 8000 V for 3.5 h. All gradients were linear. After
isoelectric focusing the strips were incubated for 15 min with 2% DTT in
equilibration buffer (50 mM Tris-HCl, pH 8.8, 6 M urea, 30% glycerol, 2%
SDS and a trace of bromphenol blue), followed by 15 min with 2.5%
iodoacetamide in the same buffer. For the second dimension, proteins were
separated in 15% polyacrylamide gels (1.5  260  200 mm) in an Ettan™
DALTsix system (Amersham). Electrophoresis was carried out at a constant
current, 15 mA/gel for 1 h and thereafter 40 mA/gel until the bromophenol
blue dye front was one cm from the gel bottom.
Coomassie staining. The gels were fixed over night with 2% phosphoric
acid in 30% ethanol, washed for 3  20 min in 2% phosphoric acid, and
equilibrated for 30 min in equilibration buffer (2% phosphoric acid/5%
aluminium sulphate/10% ethanol). The gels were then stained for 2 d in
0.01% Coomassie brilliant blue G-250 in equilibration buffer, and destained in
water.
In-gel digestion and protein fingerprinting. The gel spots were manually
excised and digested with trypsin using a MassPREP robotic protein handling
system (Micromass/Waters), employing a protocol described (17). Tryptic
fragments were analyzed by MALDI-MS (Voyager DE-Pro, Applied Biosys-
tems), using -cyano-4-hydroxycinnamic acid as matrix (5 mg/mL in meth-
anol:acetonitrile 1:1) and mixed 1:1 (vol/vol) with the sample. Database
searches were carried out utilizing the ProteinProspector MS-Fit program
(http://prospector.ucsf.edu/).
LC-MS/MS. Tryptic digests were analyzed by liquid chromatography
tandem mass spectrometry using Waters CapLC and Q-Tof Ultima API
instruments. Before LC-separation, digests were desalted using an LC-
Packings Nano-Precolumn Cartridge (300 m ID  1 mm; 5% Acetonitril/
0.1% formic acid; 20 L/min). A Waters Atlantis C18 column (3 m, 100 A˚ ,
75 m ID  15 cm) was used for LC separation and the peptides were eluted
with a linear gradient of 14–50% acetonitrile in 0.1% formic acid for 20 min
at 200 nL/min. Peptides were introduced into the mass spectrometer using a
Pico Tip sprayer and data-dependent acquisition was used over a mass range
of 300-2000 Da (m/z). Data analysis was performed using ProteinLynx Global
SERVER 2.1 software (PLGS 2.1, Waters) and MassLynx peptide sequence
software (version 4.0, Waters). Data sets were analyzed using the NCBI
BLAST and Mascot search engines.
RESULTS
Vernix caseosa was collected from newborns directly after
birth. The vernix proteins were extracted and separated by 2-D
gel electrophoresis using 350–450 g vernix protein per gel.
Due to low amounts of protein from each neonate, and high
inter-individual variation (5) (data not shown), material from
several (five to nine) neonates were pooled for each prepara-
tive gel. Two gels were used for protein identification which
had matching protein patterns, including areas of high back-
ground. Using a clean up system (2-D Clean Up kit, Amer-
sham), did not reduce the background (data not shown). To
better visualize the protein spots, the gels were combined
using the 2-D analysis software PDQuest (Bio-Rad) to make a
graphic picture (Fig. 1).
Most vernix proteins are of low molecular size (5), and are
consequently located to the lower region of the 2-D gel (Fig.
1). However, the 2-D gel reveals that many large proteins are
also present in the vernix extract. In total, we detected ap-
proximately 350 spots in each gel. Of these, 117 distinct
protein spots were excised from the two gels and proteins
were in-gel digested with trypsin. Using MALDI mass spec-
trometry and LC-MS/MS, 13 proteins were identified with
MALDI, 16 with LC-MS/MS and 12 with a combination of
the two methods (Table 1). Thereby, 41 proteins were identi-
fied in a total of 78 spots. Of these proteins, 16 (39%) are
involved in innate immunity and 12 (29%) have been demon-
strated to have direct antimicrobial activities.
DISCUSSION
In this study we have analyzed proteins in vernix caseosa
with 2-D gel electrophoresis. The proteins identified are given
in Table 1, and include 25 proteins novel to vernix. This is a
substantial addition to the knowledge of the composition of
vernix. Notably, several of the proteins are components of the
innate immune system, compatible with a protective role of
vernix against infection.
Vernix caseosa is a complex material. It has a high lipid
content making the material difficult to work with. Consis-
tently, a high background was seen in particular areas of the
gels. It was probably derived from a high lipid content and an
abundance of particular proteins including Hb, profilaggrin
and their fragments giving a trailing effect. This would be
supported by the fact that we found these proteins over a large
area of the gel (data not shown). To visualize the spots we
therefore used the software PDQuest to produce a computer-
ized image were the spots are clearly visible (Fig. 1).
Essentially all clearly visible spots were excised, and of the
117 protein spots analyzed, 41 proteins were identified in 78
spots. Many of the non-analyzed spots are concluded to be
modified versions of the identified proteins. Typical sets of
spots with multiple pIs but the same mass are noticed, repre-
senting differently modified proteins. Some were confirmed to
Figure 1. Graphic picture of proteins in Vernix caseosa separated on 2-D gel
electrophoresis. Numbers indicate identified spots and are the same as those
listed in (Table 1).
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Table 1. Proteins identified in vernix
Spot Protein
Accession
number Mr (kDa)/pI
MALDI-MS
coverage (%) LC-MS/MS sequences
1 Ubiquitin P62988 8.6/6.6 35 12-27
2 12-27, 43-48, 55-63
3 56
4 Cystatin A* P01040 11.0/5.4 11-22, 45-56
5 45-56, 72-89
6 70
7 77
8 84
9 77
10 64
11 53 23-30, 38-44, 45-56, 64-68
12 11-22, 45-56
13 45
14 Calgranulin A P05109 10.8/6.5 58
15 50
12 37-47
16 46
17 40
18 20
19 40
20 Calgranulin B P06702 13.2/5.7 85
21 61
22 82
23 Caspase 14** P31944 27.7/5.4 26 203-213, 225-235
24 31
25 15
26 16
27 Lysozyme P61626 16.5/9.4 29
28 56
29 Transthyretin P02766 15.9/5.5 64
30 Glycosylasparaginase† P20933 37.2/5.9 266-277
31 NGAL/lipocalin2 P80188 22.6/9.0 36-50
32 Psoriasin P31151 11.3/6.3 74
33 85
34 76
35 PLUNC Q9NP55 26.7/5.4 34 129-138, 139-152
36 95-109, 139-152
37 34
38 34
39 Hem  P69905 15.1/8.7 74
40 34
41 Hem  P68871 15.9/6.8 65
42 82
43 82
44 88
45 82
46 40
47 Hem -1 chain P69891 16.0/6.7 134-145
48 Hem -2 chain P69892 16.0/6.7 19-32, 134-145
49 Pulmonary surfactant-associated
protein B
P07988 42.1/5.3 28 225-236
50 253-264
51 253-264
52 Apolipoprotein A-1 P02647 30.8/5.6 33
53 28
54 Proteasome subunit beta type 2 P49721 22.8/6.5 20-29, 63-68
55 Serotransferrin P02787 77.0/6.8 35
56 24
57 Arginase 1 P05089 34.7/6.7 36
58 45 173-180, 181-191, 211-222,
256-267
59 Histone H2A P02261 14.0/10.9 83-89
59 Histone H2B P62807 13.8/10.3 38 101-109
26 59-74
(continued)
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contain the same protein, e.g. serotransferrin (spots 55 and 56
in Fig. 1), and others are well known to produce such patterns,
e.g. albumin (18). In addition, some proteins were localized to
several spots with both different masses and pIs. Cystatin A,
for example, was identified in ten spots with different local-
izations (spots 4–13 in Table 1 and Fig. 1), corresponding to
post-translational modifications, complex formations or poly-
morphisms. For Cystatin A, we could show by MS/MS that at
least one of the modifications was an amino acid exchange
(Table 1, spot 4). Furthermore, in spot 78 we could identify a
fragment of Mucin 7 in four different forms with multiple
amino acid exchanges (Table 1). This likely reflects polymor-
phisms since the material originated from several neonates.
Origins of the vernix proteins are multiple. First, there is a
close contact of vernix with the amniotic fluid, and therefore
an exchange of proteins between vernix and the amniotic fluid
is possible. Second, the amniotic fluid is also in contact with
the fetal lungs and vernix can therefore contain lung proteins.
Third, since the vernix material analyzed here was obtained
from neonates delivered by vaginal deliveries there is a risk of
blood contamination, consistent with the abundance of hemo-
globins detected. Finally, many vernix proteins have dermal
origins. Many of the identified proteins have been implicated
in innate immunity.
One protein now detected in vernix is LL-37 (spots 63–66).
We have previously demonstrated its presence, but only by
highly sensitive immunologic methods (4). Here, we report
that spots of LL-37 are detected by direct Coomassie staining
after 2-D gel electrophoresis of vernix extract. This demon-
strates the presence of high levels of LL-37 in vernix, more
than previously considered. A contradictory result was re-
ported recently, where LL-37 could not be detected in vernix
extract (6), most likely depending on extraction in PBS instead
of 60% acetonitrile with 1% TFA. Furthermore, fragments
were here identified from both the cathelin and the processing
regions, indicating that at least one of the identified LL-37
spots contains the unprocessed precursor and not only the
cathelin region. Interestingly, apolipoprotein A-1 (spots 52–
53), the major LL-37-binding protein in blood (19) was also
identified in vernix.
Palate lung nasal epithelial clone (PLUNC, also named
LUNX and SPURT) is a protein expressed in the upper
airways (20). This indicates that the PLUNC detected in
vernix probably originates from the airways of the fetus. It
Table 1. Continued
Spot Protein
Accession
number Mr (kDa)/pI
MALDI-MS
coverage (%) LC-MS/MSsequences
60 Histone H3 P68431 15.3/11.1 58-64
59 Histone H4 P62805 11.2/11.4 61-68
26 61-68
60 RNase 4 P34096 16.8/9.3 83-93
61 RNase 7 Q9H1E1 17.5/9.7 62
62 SLPI P03973 14.3/9.1 72-83
63 hCAP18/LL-37 P49913 19.3/9.5 30
64 34 12-49, 50-57, 89-100, 108-118, 119-127
65 18
66 20 132-140
67 Thioredoxin P10599 11.6/4.8 9-21
5 Cytokeratin 10 P13645 59.5/5.1 19 166-177, 246-256
12 Cytokeratin 9 P35527 62.0/5.1 170-183
5 Cytokeratin 1 P04264 65.9/8.2 258-267, 444-455
12 46-65, 186-197, 444-455
68 Super oxid dismutase P00441 15.8/5.70 42 10-23, 80-91
69 22
70 Serum albumin P02768 69.4/5.92 56
50 SCCA 1/2 P29508/
P48594
1:44.6/6.4
2:44.9/5.9
11-20
71 Zn-alpha 2-glycoprotein P25311 33.9/5.6 51
72 IGFBP-1 P08833 27.9/5.11 23 38-53, 201-208
73 Annexin A1 P04083 38.6/6.6 33
74 44
75 51
76 Alpha 1-antitrypsin P01009 46.7/5.4 34
77 Epididymal secretory protein P61916 16.6/7.6 36-51
78 Mucin 7‡ NP_689504 39.2/9.0 74-86
Bold type indicates proteins reported to exhibit antimicrobial activity.
* Cystatin A tryptic fragments were identified both with and without the first methionine. An amino acid exchange of Q to R was also observed in spot 4.
** All tryptic fragments of caspase 14 were located in the C-terminal region.
† The sequenced peptide in glycosylasparaginase was located in chain  with a Mr/pI of 15.1 kDa/7.6.
‡ The mucin 7 fragment was identified in four different forms with amino acid exchanges at positions 79 (N to D), 80 (N to D), 84 (F to L) and 86 (N to K).
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was here found in multiple spots (spots 35–38), demonstrating
the presence of several PLUNC isoforms in vernix. PLUNC
isoform formation has previously been described in human
nasal lavage fluid and modifications such as truncation, gly-
cosylation, phosphorylation and de-amidation were proposed
(21). PLUNC displays sequence homology and predicted
structure similarity to the LPS binding proteins LBP and
Bactericidal/Permeability Increasing protein (BPI) (22) and
has been shown to be able to bind LPS (21). In rats, PLUNC
is up-regulated in nasal respiratory epithelium upon olfactory
neuronal injury, suggesting that PLUNC can provide protec-
tion to infection after injury (23). Because of these properties
the family of PLUNC proteins has been proposed to have host
defense functions (22,24) and to work as sensors of Gram-
negative bacteria in the oral cavity (24).
Neutrophil gelatinase-associated lipocalin (NGAL, also
named human neutrophil lipocalin, uterocalin) is a bacterio-
static protein that interferes with the iron acquisition in bac-
teria through specific binding to bacterial chatecolate-type
ferric siderophores (25). It is mainly expressed in neutrophils
and tissues exposed to microbes such as trachea, uterus and
colon (26). Hence, NGAL detected in vernix (spot 31) can
originate from the maternal uterus and the neonatal respiratory
tract or skin.
Ribonuclease 7 (RNase 7) was first isolated from stratum
corneum of the skin and is an antimicrobial ribonuclease (27).
RNase 7 is constitutively expressed in epithelial tissues in-
cluding skin, respiratory tract, and uterus (27) but also in other
tissues such as liver and kidney (28). It has also been shown
to be induced in keratinocytes by certain bacteria (27). RNase
7 exhibits a broad spectrum of antimicrobial activity against
many pathogens including vancomycin-resistant Enterococ-
cus faecium (27). Our finding of RNase 7 in vernix (spot 61)
suggests that it also is expressed in fetal skin thereby enhanc-
ing its role in innate immunity. Interestingly, another member
of the ribonuclease A superfamily, RNase 4, was also identi-
fied in vernix (spot 60).
Annexins (spots 73–75) are a family of proteins that bind to
phospholipids and carbohydrates in the presence of calcium
ions. Annexin I has been shown to bind surface molecules of
both Gram-positive and Gram-negative bacteria, i.e., lipotei-
choic acids (29) and Lipid A (30). It has been shown to reduce
neutrophil and monocyte infiltration in animal models (31–
33), and to suppress the attachment of Staphylococcus aureus
to macrophages (29), activities that give Annexin I a role in
inflammation.
In conclusion, our proteome analysis defines many proteins
novel to vernix, with over one third related to innate immu-
nity. This constitutes a substantial improvement to our knowl-
edge of vernix and supports the conclusion that antimicrobial
protection of the fetus is a major function of vernix.
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